| abstract |
The invention provides {(S) -3- [6- (6-methoxy-5-methyl-pyridin-3-yl) -5,6,7,8-tetrahydro-pyrido [4,3-d] Crystalline anhydrous form, crystalline solvate form and / or salt form of pyrimidin-4-yloxy] -pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl) -methanone, such as crystalline salt form or 1-{(S) -3- [6- (6-methoxy-5-trifluoromethyl-pyridin-3-yl) -5,6,7,8-tetrahydro-pyrido [4,3- d] salt forms, such as crystalline salt forms of pyrimidin-4-ylamino] -pyrrolidin-1-yl} -propan-1-one; Pharmaceutical compositions and combinations comprising these forms, as well as methods of using these forms, such as pharmaceutical compositions and combinations thereof, for the treatment of diseases. |